Figure 3: D4736.54f has different roles in the recognition of Anta XV and LY2940680. | Nature Communications

Figure 3: D4736.54f has different roles in the recognition of Anta XV and LY2940680.

From: Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs

Figure 3

(ai) The receptor structures in SMO_Anta XV, SMO_SANT1 and SMO_LY2940680 (PDB i.d.: 4JKV, molecule A) complexes are shown in green, yellow and salmon, respectively. Ligand structures of Anta XV, SANT1 and LY2940680 are shown in green, orange and magenta carbons, respectively. (a) Superposition of SMO_LY2940680 and SMO_Anta XV structures near ECL3. The conformational change of F484ECL3 induced by LY2940680 binding is shown by an arrow. See also Supplementary Fig. 5 for comparison with SMO_SANT1 structure. (b) Superposition of the SMO_SANT1, SMO_Anta XV and SMO_LY2940680 structures reveals a different conformation of ECL3 in LY2940680 bound structure (shown by arrow). (c) Localization of ECL3 (green) and polar residue cluster (R4005.43f, D4736.54f and E5187.38f, red) in SMO. (d) Superposition of the binding poses of LY2940680 and Anta XV reveals distinct orientations (dashed lines parallel to the equatorial bonds of the six-membered chair conformation rings) of the six-membered rings connected to the phthalazine ring. The shift of the phthalazine of LY2940680 compared with that of Anta XV is shown by arrow. (e) Superposition of SMO_Anta XV and SMO_SANT1 structures. (f) Superposition of SMO_LY2940680 and SMO_SANT1 structures. (g) Superposition of SMO_LY2940680 and SMO_Anta XV structures. Ligand-induced shifts of helices are shown by arrows. (h) Superposition of the ligand binding pocket residues of SMO_SANT1, SMO_Anta XV and SMO_LY2940680 structures. Ligand interaction-induced conformation change at D4736.54f is indicated by arrow. (i) Polar residue cluster in the ligand binding pocket of the SMO_Anta XV structure. Polar interactions are shown as dashed lines. (j) ΔpKi values (pKi wild-type(wt)–pKi mutants (mut)) of the D4736.54fA and E5187.38fA mutants for different SMO receptor ligands in 3H-cyclopamine competition experiments. Shown in the graph are mean±s.e.m. of 3–4 independent experiments, see also Supplementary Table 2.

Back to article page